PDCD1 and non-small cell lung carcinoma: In addition, Nishioka et al., in a retrospective study of 156 patients with NSCLC treated with anti-PD-1/PD-L1 inhibitor monotherapy, showed no relationship between muscle mass and ORR or PFS [31].